Eli Lilly Pulls Sarcoma Drug from the Market After Failed Trial

April 29, 2019

Eli Lily is withdrawing Lartruvo from the market after a phase 3 clinical trial deemed the cancer drug ineffective, according to the Wall Street Journal.

A phase 3 clinical trial for Eli Lilly’s Lartruvo found that it did not improve survival rates for patients with soft tissue sarcoma. Lilly is working to establish a program for current Lartruvo patients to continue using the therapy as long as they have been informed of the risks and results of the clinical trial.

“Advanced soft tissue sarcoma is a rare and difficult-to-treat cancer. Establishing this program will give patients who are currently taking Lartruvo the opportunity to continue their treatment program uninterrupted,” president of Lilly Oncology Anna White said in a press release.

Read the full WSJ story.